Profund Advisors LLC lowered its holdings in shares of Syneos Health Inc (NASDAQ:SYNH) by 8.7% during the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 21,347 shares of the company’s stock after selling 2,045 shares during the period. Profund Advisors LLC’s holdings in Syneos Health were worth $1,091,000 as of its most recent SEC filing.
Other institutional investors have also made changes to their positions in the company. ClariVest Asset Management LLC raised its stake in shares of Syneos Health by 267.9% in the 1st quarter. ClariVest Asset Management LLC now owns 174,541 shares of the company’s stock worth $9,035,000 after buying an additional 127,098 shares in the last quarter. Boston Advisors LLC bought a new stake in shares of Syneos Health in the 2nd quarter worth $1,257,000. Geode Capital Management LLC raised its stake in shares of Syneos Health by 7.3% in the 4th quarter. Geode Capital Management LLC now owns 738,567 shares of the company’s stock worth $29,061,000 after buying an additional 50,175 shares in the last quarter. BB&T Corp raised its stake in shares of Syneos Health by 8.1% in the 2nd quarter. BB&T Corp now owns 8,749 shares of the company’s stock worth $448,000 after buying an additional 656 shares in the last quarter. Finally, Tiverton Asset Management LLC bought a new stake in shares of Syneos Health in the 2nd quarter worth $279,000.
Shares of NASDAQ SYNH traded up $0.75 during mid-day trading on Monday, reaching $55.42. The company had a trading volume of 13,926 shares, compared to its average volume of 389,826. The company has a current ratio of 0.89, a quick ratio of 0.89 and a debt-to-equity ratio of 0.99. The stock has a market cap of $5.62 billion, a PE ratio of 21.08, a P/E/G ratio of 1.90 and a beta of 1.51. The company has a 50-day moving average price of $51.16 and a two-hundred day moving average price of $48.13. Syneos Health Inc has a 1-year low of $36.26 and a 1-year high of $56.34.
Syneos Health (NASDAQ:SYNH) last issued its earnings results on Tuesday, August 6th. The company reported $0.61 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.59 by $0.02. The business had revenue of $1.17 billion for the quarter, compared to analysts’ expectations of $1.15 billion. Syneos Health had a return on equity of 9.82% and a net margin of 0.36%. The company’s quarterly revenue was up 8.8% on a year-over-year basis. During the same period in the previous year, the firm posted $0.62 EPS. On average, research analysts expect that Syneos Health Inc will post 2.73 EPS for the current year.
A number of equities analysts recently issued reports on SYNH shares. Zacks Investment Research cut Syneos Health from a “buy” rating to a “hold” rating and set a $55.00 target price on the stock. in a report on Tuesday, September 10th. KeyCorp lifted their target price on Syneos Health from $63.00 to $65.00 and gave the stock an “overweight” rating in a report on Tuesday, September 3rd. Credit Suisse Group lifted their target price on Syneos Health from $56.00 to $58.00 and gave the stock an “outperform” rating in a report on Friday, August 23rd. UBS Group lifted their target price on Syneos Health from $53.50 to $57.00 and gave the stock a “neutral” rating in a report on Thursday, August 29th. Finally, SunTrust Banks lifted their target price on Syneos Health to $68.00 and gave the stock a “buy” rating in a report on Wednesday, August 7th. Five research analysts have rated the stock with a hold rating and six have given a buy rating to the company. The company currently has a consensus rating of “Buy” and an average price target of $58.63.
Syneos Health Profile
Syneos Health, Inc operates as an integrated biopharmaceutical solutions company in North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates through two segments, Clinical Solutions and Commercial Solutions. The Clinical Solutions segment offers various clinical development services spanning Phase I to Phase IV, including full-service global studies, as well as clinical monitoring, investigator recruitment, patient recruitment, data management, and study startup to assist customers with drug development process.
Featured Story: Why do commodities matter?
Receive News & Ratings for Syneos Health Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Syneos Health and related companies with MarketBeat.com's FREE daily email newsletter.